The Myc family’s dominant oncogenes are routinely overexpressed in both SCLC and NSCLC, although the K-RAS oncogene is never mutated in SCLC but is in 30% of NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.